DREN BIO
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
DREN BIO
Industry:
Biotechnology Health Care Life Science
Founded:
2019-01-01
Address:
Foster City, California, United States
Country:
United States
Website Url:
http://www.drenbio.com
Total Employee:
1+
Status:
Active
Total Funding:
130.05 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Google Universal Analytics Font Awesome Global Site Tag
Similar Organizations
hC Bioscience
hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA.
Kytopen
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Q-State Biosciences
Q-State has developed world-leading technologies and proprietary approaches for probing rare and genetic CNS conditions.
Current Advisors List
Current Employees Featured
Founder
Investors List
HBM Partners
HBM Partners investment in Series B - Dren Bio
ArrowMark Partners
ArrowMark Partners investment in Series B - Dren Bio
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Dren Bio
BVF Partners
BVF Partners investment in Series B - Dren Bio
Taiho Ventures
Taiho Ventures investment in Series B - Dren Bio
Aisling Capital
Aisling Capital investment in Series B - Dren Bio
Revelation Partners
Revelation Partners investment in Series B - Dren Bio
SR One
SR One investment in Series B - Dren Bio
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - Dren Bio
Mission BioCapital
Mission BioCapital investment in Series B - Dren Bio
Official Site Inspections
http://www.drenbio.com
- Host name: 215.246.12.198.host.secureserver.net
- IP address: 198.12.246.215
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Dren Bio"
Executive Team - Dren Bio
Dren Bio Team, Chief Executice officers, Board members, Science Board memebers. Our executive team has significant expertise covering both the discovery and development of …See details»
Dren Bio - Crunchbase Company Profile & Funding
Contact Email [email protected] Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease …See details»
DREN BIO, INC. Company Profile | Foster City, CA | Competitors ...
Find company research, competitor information, contact details & financial data for DREN BIO, INC. of Foster City, CA. Get the latest business insights from Dun & Bradstreet.See details»
Dren Bio, Inc. | LinkedIn
Dren Bio, Inc. | 2,296 followers on LinkedIn. Dren Bio is a Foster City, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and …See details»
Dren Bio Company Profile 2024: Valuation, Funding & Investors
Www.drenbio.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. 384 Foster City Boulevard; Foster City, CA 94404; United StatesSee details»
Dren Bio, Inc. Company Overview, Contact Details & Competitors
[email protected]: 50%. See more formats. Frequently Asked Questions Where is Dren Bio, Inc. 's headquarters located? Dren Bio, Inc. 's main headquarters is located at 384 Foster City …See details»
Dren Bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Www.drenbio.com. Startups | Holding Company | 2019 | California, United States | 10-50 | www.drenbio.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational …See details»
Dren Bio - Company Profile - Tracxn
Nov 28, 2024 Dren Bio - Developer of therapeutic antibodies for the treatment of cancer, autoimmune, and other serious diseases. Raised a total funding of $156M over 3 rounds from …See details»
Dren Bio Company Profile - Office Locations, Competitors ... - Craft
Dren Bio has 5 employees at their 1 location and $65.1 m in total funding,. See insights on Dren Bio including office locations, competitors, revenue, financials, executives, subsidiaries and …See details»
Dren Bio - Overview, News & Similar companies | ZoomInfo.com
Oct 16, 2023 Dren Bio contact info: Phone number: (415) 737-5277 Website: www.drenbio.com What does Dren Bio do? Dren Bio is a California based biotechnology company developing …See details»
Careers / Dren Bio
This is an opportunity to develop a substantially diverse skill set hands-on and to grow with the organization, and therefore we are seeking an individual with an energetic curiosity for …See details»
Dren Bio | Leukemia and Lymphoma Society
Dec 12, 2022 The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. Please check with your …See details»
Dren Bio Announces Strategic Collaboration with Novartis to …
FOSTER CITY, Calif., July 24, 2024--Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for CancerSee details»
Dren Bio Announces Strategic Collaboration with Novartis to …
Jul 24, 2024 Dren Bio, Inc., a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune, and other serious diseases, today …See details»
Dren Bio and Novartis link on bispecific antibodies for cancer
Jul 25, 2024 Novartis biomedical research oncology global head Shiva Malek stated: “Our agreement with Dren Bio is a promising opportunity to discover novel bispecific antibody …See details»
With $1B already in for Dren Bio, Pfizer signs on to $65M round
Jun 14, 2022 Dren Bio—a biotech developing therapeutic antibodies for patients with cancer and autoimmune diseases—has closed a $65 million series B financing round, with new investor …See details»
Dren Bio announces a $60M Series A financing | Business Wire
Oct 16, 2020 SAN CARLOS, Calif.--(BUSINESS WIRE)--Dren Bio, Inc., a company developing powerful protein-engineering technologies for depletion of cells, protein aggregates and other …See details»
Novartis pens $150M upfront bispecifics deal with Dren Bio
Jul 24, 2024 Dren Bio’s lead asset is DR-01, which targets autoreactive CD8 T cells and is currently in phase 2 trials for cytotoxic lymphomas. The biotech's platform is designed to …See details»
Dren Bio
Targeted Myeloid Engager and Phagocytosis Platform. Dren Bio’s Targeted Myeloid Engager and Phagocytosis Platform is a bispecific antibody-based technology that induces potent depletion …See details»